Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Swedberg

Showing results (311-320 of 471) with videos related to

Pageof 48
Sort By:
JAMA Cardiology|December 8, 2022
Associations Between New York Heart Association Classification, Objective Measures, and Long-term Prognosis in Mild Heart Failure: A Secondary Analysis of the PARADIGM-HF TrialLuis E Rohde, André Zimerman, Muthiah Vaduganathan, et al.
Circulation|November 30, 2016
Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction: Insights From the PARADIGM-HF Study (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial)Wilson Nadruz, Brian L Claggett, John J McMurray, et al.
European Heart Journal|September 27, 2005
Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart FailureMattie J Lenzen, Eric Boersma, Wilma J M Scholte Op Reimer, et al.
Journal of the American College of Cardiology|July 16, 2013
Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity)Chih M Wong, Nathaniel M Hawkins, Pardeep S Jhund, et al.
Circulation. Heart Failure|April 13, 2018
Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure)Orly Vardeny, Brian Claggett, Jessica Kachadourian, et al.
JACC. Heart Failure|September 13, 2020
Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF AnalysisLuis E Rohde, Neal A Chatterjee, Muthiah Vaduganathan, et al.
JAMA|May 29, 2024
Revisiting Race and the Benefit of RAS Blockade in Heart Failure: A Meta-Analysis of Randomized Clinical TrialsLi Shen, Matthew M Y Lee, Pardeep S Jhund, et al.
American Heart Journal|December 1, 2012
Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST TrialRobert J Mentz, Matthew J Chung, Mihai Gheorghiade, et al.
European Journal of Heart Failure|September 6, 2016
Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustmentNathaniel M Hawkins, Pardeep S Jhund, Andrea Pozzi, et al.
European Journal of Heart Failure|February 13, 2018
Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrumLars H Lund, Brian Claggett, Jiankang Liu, et al.
Pageof 48

Showing results (311-320 of 471) with videos related to

Sort By:
Pageof 48
JAMA Cardiology|December 8, 2022
Associations Between New York Heart Association Classification, Objective Measures, and Long-term Prognosis in Mild Heart Failure: A Secondary Analysis of the PARADIGM-HF TrialLuis E Rohde, André Zimerman, Muthiah Vaduganathan, et al.
Circulation|November 30, 2016
Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction: Insights From the PARADIGM-HF Study (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial)Wilson Nadruz, Brian L Claggett, John J McMurray, et al.
European Heart Journal|September 27, 2005
Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart FailureMattie J Lenzen, Eric Boersma, Wilma J M Scholte Op Reimer, et al.
Journal of the American College of Cardiology|July 16, 2013
Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity)Chih M Wong, Nathaniel M Hawkins, Pardeep S Jhund, et al.
Circulation. Heart Failure|April 13, 2018
Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure)Orly Vardeny, Brian Claggett, Jessica Kachadourian, et al.
JACC. Heart Failure|September 13, 2020
Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF AnalysisLuis E Rohde, Neal A Chatterjee, Muthiah Vaduganathan, et al.
JAMA|May 29, 2024
Revisiting Race and the Benefit of RAS Blockade in Heart Failure: A Meta-Analysis of Randomized Clinical TrialsLi Shen, Matthew M Y Lee, Pardeep S Jhund, et al.
American Heart Journal|December 1, 2012
Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST TrialRobert J Mentz, Matthew J Chung, Mihai Gheorghiade, et al.
European Journal of Heart Failure|September 6, 2016
Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustmentNathaniel M Hawkins, Pardeep S Jhund, Andrea Pozzi, et al.
European Journal of Heart Failure|February 13, 2018
Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrumLars H Lund, Brian Claggett, Jiankang Liu, et al.
Pageof 48